Paradigm Genetics, on Notice from Nasdaq, Plans to Appeal Decision | GenomeWeb

NEW YORK, Jan. 29-Joining the small crowd of genomics firms that are on the verge of losing a spot on the trading floor, Paradigm Genetics said today that Nasdaq notified the company on Jan. 24 that it is now subject to delisting.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.